
Arvee Laboratories (India): Should You Buy, Hold, or Sell Right Now?
Arvee Laboratories (India) share price Rs 163.93 (NSE), well off its 52-week high. 52-week range Rs 129.11 to Rs 290.78. Trades at 44.55 times earnings.
Updated: 8 Sept 2026 • 11:05 am
Posted by:

Quick Answer
Arvee Laboratories (India) Ltd share price is trading around Rs 164, more than 43 percent below its 52-week high of Rs 290.78 but above its 52-week low of Rs 129.11. This small pharmaceutical formulations manufacturer trades at a price to earnings ratio of 44.55, roughly in line with the pharma sector average near 40.7 times, with a return on equity of 7.48 percent. Current-quarter financial data was not consistently available across public sources at the time of writing, so this article relies on available trailing metrics and urges appropriate caution given the data limitations involved.
Arvee Laboratories (India) share price has fallen more than 43 percent from its 52-week high of Rs 290.78, with Arvee Laboratories (India) share price now trading near Rs 164 on the NSE, above its 52-week low of Rs 129.11. Given limited current financial data availability, this article presents what is known plainly before laying out a balanced view.
This Arvee Laboratories (India) overview walks through the available valuation data, the significant data limitations, and the technical setup, using figures sourced from public filings, with appropriate caveats throughout.
Click Here – Get Free Investment Predictions
About Arvee Laboratories (India)
Before deciding on Arvee Laboratories (India) share price, it helps to understand the underlying business. Arvee Laboratories (India) Ltd. manufactures pharmaceutical formulations, serving domestic and possibly export markets with branded and generic medicines.
Current-quarter financial data for the company was not consistently available across public sources at the time of writing, meaning investors should seek the company's latest exchange filings directly for more current information before making any decision.
Arvee Laboratories (India) Share Price Today: Key Levels
The table below summarises where Arvee Laboratories (India) share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Arvee Laboratories CMP (NSE) | Rs 163.93 |
| 52-Week High | Rs 290.78 |
| 52-Week Low | Rs 129.11 |
| Market Capitalisation | Approximately Rs 181 crore |
Arvee Laboratories (India) share price is trading well below its 52-week high, reflecting limited market attention typical of this small, thinly-traded pharmaceutical company.
Check the Univest Screener for Live Stock Data
Arvee Laboratories (India) Financial Performance
The Arvee Laboratories (India) share price trend is closely tied to how these numbers evolve each quarter. Current-quarter financial data for Arvee Laboratories (India) was not consistently available across public sources at the time of writing. The company's trailing twelve-month figures show a positive EPS of Rs 3.68 and a return on equity of 7.48 percent, indicating the business is currently generating a modest positive return.
Investors should refer directly to the company's latest exchange filings for updated quarterly figures before drawing conclusions about the current trend, given the limited publicly available recent data.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Trailing twelve months | Not fully disclosed publicly | EPS Rs 3.68, ROE 7.48% | Current-quarter data not consistently available |
Valuation Check: Is Arvee Laboratories (India) Share Price Expensive?
Any view on Arvee Laboratories (India) share price should start from these valuation multiples. Arvee Laboratories (India) share price currently reflects a price to earnings ratio of about 44.55 times trailing earnings, roughly in line with the broader pharmaceutical sector average of roughly 40.7 times. The price to book ratio stands near 5.4 times.
Debt to equity of 0.03 is very low. Given the very small scale and data limitations, standard valuation comparisons carry reduced reliability here, though the low leverage is a positive structural feature.
Technical Signals: What the Chart Shows
Price action here often foreshadows the next move in Arvee Laboratories (India) share price. Arvee Laboratories (India) share price is currently positioned more than 43 percent below its 52-week high of Rs 290.78 and above its 52-week low of Rs 129.11. Given the very thin trading volumes typical of this stock, technical signals should be read with particular caution.
Investors should track Arvee Laboratories (India) share price alongside any updated company disclosures, rather than relying on price action alone given the limited data currently available.
Download the Univest iOS App or Univest Android App to track Arvee Laboratories (India)'s live price and technical levels.
Shareholding Pattern
Shifts here can influence Arvee Laboratories (India) share price more than headline news on some sessions. Arvee Laboratories (India) is a small, promoter-led pharmaceutical formulations manufacturer. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company's latest exchange filing.
Why Investors Are Watching Arvee Laboratories (India)
- Very low financial leverage: A debt to equity ratio of just 0.03 gives the company significant financial flexibility.
- Modest positive trailing profitability: A positive trailing EPS and a return on equity of 7.48 percent indicate the business is currently generating a modest positive return.
Risks and Factors to Watch
- Very significant data limitations: Current-quarter financial data was not consistently available across public sources at the time of writing, creating a meaningful information gap for investors.
- Very small scale and thin liquidity: As a small company with a market capitalisation of approximately Rs 181 crore, this stock carries elevated risks typical of very small, thinly-traded companies.
- Pharmaceutical formulations competitive market: Arvee Laboratories (India) competes against numerous domestic and international pharmaceutical formulations manufacturers.
- Significant pullback from 52-week high: The stock has fallen more than 43 percent from its high, and investors should understand the reasons behind this decline before assuming the current level represents value.
Arvee Laboratories (India) Share Price Target: What the Data Suggests
Until then, Arvee Laboratories (India) share price remains best tracked through live, verified data rather than a single fixed number. Arvee Laboratories (India) does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time, given the limited current data available.
Investors considering this stock should seek the company's most recent exchange filings directly, and should consult a SEBI-registered investment adviser given the very small scale and data limitations involved.
Arvee Laboratories (India): Should You Buy, Hold, or Sell Right Now?
This is the core question behind Arvee Laboratories (India) share price right now. The Arvee Laboratories (India) buy or sell decision should account for the very significant data limitations currently present.
The case for buying: Only investors who have independently sourced more current company filings and are satisfied with what they find may consider a position, given the elevated risk and small scale involved.
The case for holding: Existing shareholders who already accept this risk profile and data limitation may choose to continue holding.
The case for avoiding: Most investors, particularly those preferring companies with clear, current financial disclosure, would reasonably prefer to avoid this stock until more recent data becomes available.
Given the substantial data limitations here, consult a SEBI-registered investment adviser before proceeding.
Conclusion
Arvee Laboratories (India) share price reflects a small pharmaceutical formulations manufacturer with significant gaps in publicly available current financial data, trading well below its 52-week high. This is a niche, thinly-traded stock requiring particular diligence. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is Arvee Laboratories a good stock to buy right now?
Ans. Arvee Laboratories (India) has very limited current financial data publicly available, with a trailing return on equity of 7.48 percent. Given the significant data gaps and small scale, this suits only investors who have independently sourced updated company filings.
Q2. What is the Arvee Laboratories share price today?
Ans. Arvee Laboratories (India) share price is trading around Rs 164 on the NSE. The stock's 52-week high is Rs 290.78 and its 52-week low is Rs 129.11.
Q3. What is the Arvee Laboratories share price target?
Ans. Arvee Laboratories (India) does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time, given the very significant data limitations.
Q4. What does Arvee Laboratories manufacture?
Ans. Arvee Laboratories (India) manufactures pharmaceutical formulations.
Q5. What is Arvee Laboratories' market capitalisation?
Ans. Arvee Laboratories (India) has a market capitalisation of approximately Rs 181 crore, making it a very small, thinly-traded stock.
Q6. Is Arvee Laboratories debt free?
Ans. Arvee Laboratories (India) carries a debt to equity ratio of just 0.03, reflecting an almost entirely debt free balance sheet.
Recent Articles

Is Andhra Paper a Good Buy After Its Q1 FY27 Results?
8 September 2026

Is Antelopus Selan Energy a Good Buy After Its Q1 FY27 Results?
8 September 2026

Is Amines and Plasticizers a Good Buy After Its Q1 FY27 Results?
8 September 2026

Ansal Properties & Infrastructure: Should You Buy, Hold, or Sell Right Now?
8 September 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Is Andhra Paper a Good Buy After Its Q1 FY27 Results?
Is Antelopus Selan Energy a Good Buy After Its Q1 FY27 Results?
Is Amines and Plasticizers a Good Buy After Its Q1 FY27 Results?
Ansal Properties & Infrastructure: Should You Buy, Hold, or Sell Right Now?
Is Amagi Media Labs a Good Buy After Its Q1 FY27 Results?
Popular this week
Art Nirman: Should You Buy, Hold, or Sell Right Now?

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





